User profiles for Ida K. Haugen

Ida Kristin Haugen

Verified email at diakonsyk.no
Cited by 7530

[HTML][HTML] OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis

…, M Bhandari, FJ Blanco, R Espinosa, IK Haugen… - Osteoarthritis and …, 2019 - Elsevier
Objective To update and expand upon prior Osteoarthritis Research Society International (OARSI)
guidelines by developing patient-focused treatment recommendations for individuals …

Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines

…, O Bruyère, C Cooper, IK Haugen… - Nature Reviews …, 2021 - nature.com
Knee osteoarthritis (OA) is a heterogeneous disease associated with substantial effects on
quality of life, and its clinical management is difficult. Among the several available guidelines …

Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study

IK Haugen, M Englund, P Aliabadi, J Niu… - Annals of the …, 2011 - ard.bmj.com
Ida K Haugen1, … Tore K Kvien1, … Correspondence to Ida K Haugen, Department of
Rheumatology, Diakonhjemmet Hospital, PO Box 23, Vinderen, 0319 Oslo, Norway; haugen_ida{at}…

2018 update of the EULAR recommendations for the management of hand osteoarthritis

…, KS Dziedzic, E Greibrokk, IK Haugen… - Annals of the …, 2019 - ard.bmj.com
Since publication of the European League Against Rheumatism (EULAR) recommendations
for management of hand osteoarthritis (OA) in 2007 new evidence has emerged. The aim …

MRI-based semiquantitative scoring of joint pathology in osteoarthritis

A Guermazi, FW Roemer, IK Haugen… - Nature Reviews …, 2013 - nature.com
The use of MRI techniques to investigate tissue pathology has become increasingly
widespread in osteoarthritis (OA) research. Semiquantitative assessment of the joints by expert …

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with …

M Kloppenburg, C Peterfy, IK Haugen… - Annals of the …, 2019 - ard.bmj.com
Objective To assess the efficacy, safety, pharmacokinetics and pharmacodynamics of the
anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab (ABT-981) in …

Osteoarthritis endotype discovery via clustering of biochemical marker data

…, M Kloppenburg, FJ Blanco, IK Haugen… - Annals of the …, 2022 - ard.bmj.com
Objectives Osteoarthritis (OA) patient stratification is an important challenge to design
tailored treatments and drive drug development. Biochemical markers reflecting joint tissue …

Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham Heart Study

IK Haugen, VS Ramachandran, D Misra… - Annals of the …, 2015 - ard.bmj.com
Objectives To study whether hand osteoarthritis (OA) is associated with increased mortality
and cardiovascular events in a large community based cohort (Framingham Heart Study) in …

[HTML][HTML] A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis–the HUMOR trial

D Aitken, LL Laslett, F Pan, IK Haugen, P Otahal… - Osteoarthritis and …, 2018 - Elsevier
Objective To assess the efficacy of adalimumab in patients with erosive hand osteoarthritis (OA).
Method Patients >50 years old, meeting the American College of Rheumatology (ACR) …

[HTML][HTML] Multimodal multidisciplinary management of patients with moderate to severe pain in knee osteoarthritis: a need to meet patient expectations

…, M de Wit, A Fioravanti, NR Fuggle, IK Haugen… - Drugs, 2022 - Springer
Knee osteoarthritis (OA) is one of the most common and disabling medical conditions. In the
case of moderate to severe pain, a single intervention may not be sufficient to allay …